Patents by Inventor Thomas Joseph Logan

Thomas Joseph Logan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110150860
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 7, 2010
    Publication date: June 23, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rory A.J. Curtis, Thomas Joseph Logan, Maria Alexandra Glucksmann, Rachel E. Meyers, Mark J. Williamson, Laura A. Rudolph-Owen, Miyoung Chun, Fong-Ying Tsai
  • Patent number: 7820403
    Abstract: The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: October 26, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Thomas Joseph Logan
  • Publication number: 20100009384
    Abstract: The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 2, 2008
    Publication date: January 14, 2010
    Inventors: Rosana Kapeller-Libermann, Thomas Joseph Logan
  • Publication number: 20080241133
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 24, 2008
    Publication date: October 2, 2008
    Inventors: Rory A. J. Curtis, Thomas Joseph Logan, Maria Alexandra Glucksmann, Rachel E. Meyers, Mark J. Williamson, Laura A. Rudolph-Owen, Miyoung Chun, Fong-Ying Tsai
  • Patent number: 7410785
    Abstract: The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: August 12, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Thomas Joseph Logan
  • Patent number: 7157240
    Abstract: The invention provides isolated nucleic acids molecules, designated MID 4460 nucleic acid molecules, which encode novel tyrosine phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MID 4460 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MID 4460 gene has been introduced or disrupted. The invention still further provides isolated MID 4460 proteins, fusion proteins, antigenic peptides and anti-MID 4460 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 2, 2007
    Assignee: Bayer Healthcare AG
    Inventor: Thomas Joseph Logan
  • Patent number: 7052888
    Abstract: The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: May 30, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Thomas Joseph Logan
  • Publication number: 20040157221
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 27, 2003
    Publication date: August 12, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rory A. J. Curtis, Thomas Joseph Logan, Maria Alexandra Glucksmann, Rachel E. Meyers, Mark J. Williamson, Laura A. Rudolph-Owen, Miyoung Chun, Fong-Ying Tsai
  • Patent number: 6686185
    Abstract: The invention provides isolated nucleic acids molecules, designated 25934 nucleic acid molecules, which encode a novel desaturase family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25934 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25934 gene has been introduced or disrupted. The invention still further provides isolated 25934 proteins, fusion proteins, antigenic peptides and anti-25934 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods for modulating fatty acid metabolism utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing cardiovascular disorders, such atherosclerosis, hypertriglyceridemia, hypercholesterolemia, and hyperlipidemia, are disclosed.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 3, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Thomas Joseph Logan, Maria Alexandra Glucksmann
  • Publication number: 20040009501
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 27, 2003
    Publication date: January 15, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rory A. J. Curtis, Thomas Joseph Logan, Maria Alexandra Glucksmann, Rachel E. Meyers, Mark J. Williamson, Laura A. Rudolph-Owen, Miyoung Chun, Fong-Ying Tsai
  • Publication number: 20030152574
    Abstract: The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Application
    Filed: December 10, 2002
    Publication date: August 14, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Thomas Joseph Logan, Miyoung Chun
  • Publication number: 20030119742
    Abstract: The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease.
    Type: Application
    Filed: November 5, 2002
    Publication date: June 26, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Katherine M. Galvin, Thomas Joseph Logan, Miyoung Chun
  • Publication number: 20030109044
    Abstract: The invention provides isolated nucleic acids molecules, designated 279 nucleic acid molecules, which encode human G protein-coupled receptor (GPCR) family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 279 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 279 gene has been introduced or disrupted. The invention still further provides isolated 279 proteins, fusion proteins, antigenic peptides and anti-279 antibodies. Methods utilizing compositions of the invention to treat, prevent or diagnose angiogenic disorders, e.g., cardiovascular and cancerous disorders, are also provided.
    Type: Application
    Filed: October 9, 2002
    Publication date: June 12, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Thomas Joseph Logan, Katherine M. Galvin
  • Publication number: 20030077638
    Abstract: The invention provides isolated nucleic acids molecules, designated MID 4460 nucleic acid molecules, which encode novel tyrosine phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MID 4460 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MID 4460 gene has been introduced or disrupted. The invention still further provides isolated MID 4460 proteins, fusion proteins, antigenic peptides and anti-MID 4460 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 17, 2002
    Publication date: April 24, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Thomas Joseph Logan
  • Publication number: 20030044948
    Abstract: The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: August 21, 2001
    Publication date: March 6, 2003
    Inventors: Rosana Kapeller-Libermann, Thomas Joseph Logan
  • Publication number: 20020076786
    Abstract: The invention provides isolated nucleic acid molecules, designated COE-1 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing COE-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a COE-1 gene has been introduced or disrupted. The invention still further provides isolated COE-1 proteins, fusion proteins, antigenic peptides and anti-COE-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 29, 2001
    Publication date: June 20, 2002
    Inventors: Rory A.J. Curtis, Thomas Joseph Logan